Triplet Therapeutics to Present at Cowen 40th Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Triplet Therapeutics, Inc., a biotechnology company harnessing new insights from human genetics to develop transformative treatments for repeat expansion disorders, today announced that Nessan Bermingham, Ph.D., Triplet’s co-founder, president and chief executive officer, will present at the Cowen and Company 40th Annual Health Care Conference taking place in Boston March 2-4, 2020.

Dr. Bermingham will provide an overview of Triplet’s approach and recent progress to develop transformative treatments for repeat expansion disorders, a group of more than 40 known genetic diseases including Huntington’s disease, spinocerebellar ataxias and myotonic dystrophy. A significant body of human genetic evidence has identified one central pathway, known as the DNA damage response (DDR) pathway, that drives onset and progression across many of these disorders. Triplet is developing antisense oligonucleotide (ASO) and small interfering RNA (siRNA) therapeutics to precisely modulate the DDR mechanism that drives repeat expansion and has the potential to address repeat expansion disorders en masse.

Dr. Bermingham’s presentation details are as follows:

Date: Tuesday, March 3
Time: 2:00 - 2:25 p.m.
Location: Boston Marriott Copley Place

About Triplet Therapeutics

Triplet Therapeutics is a biotechnology company harnessing new insights from human genetics to develop transformative treatments for patients with unmet medical needs to target the underlying cause of repeat expansion disorders, a group of more than 40 known genetic diseases including Huntington’s disease, spinocerebellar ataxias and myotonic dystrophy. Triplet was founded by Nessan Bermingham, Ph.D., Atlas Venture and Andrew Fraley, Ph.D. Triplet has raised $59 million in funding to date, including its Series A funding in 2019 led by MPM Capital and Pfizer Ventures, with Atlas Venture, Invus, Partners Innovation Fund and Alexandria Venture Investments participating. Triplet is headquartered in Cambridge, Mass. For more information, please visit www.triplettx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005131/en/

Mary Carmichael
Ten Bridge Communications
[email protected]
617-413-3543

Source: Triplet Therapeutics, Inc.

You May Also Be Interested In

• Aster Guardians Global Nursing Award 2026 Names Agimol Pradeep From United Kingdom Winner of USD 250,000 Prize
• 7 Best Cryptos in 2026 to Watch: Apeing’s Crypto Presale Making Headlines With Over $80K Raised
• Sean Kirtz and Lady Hammers Earn 3rd Place at Midwest Nationals